Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

NICE guidance informed by SHTAC report on daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma

Published: 2 May 2019
Intravenous drip
NICE guidance informed by a report produced by SHTAC

The National Institute for Health and Care Excellence (NICE) has issued guidance to the National Health Service (NHS) on the use of the drugs daratumumab with bortezomib and dexamethasone as a treatment for previously treated multiple myeloma in adults, informed by a report produced by SHTAC.

NICE’s guidance recommends daratumumab (Darzalex) with bortezomib and dexamethasone for use through the Cancer Drugs Fund as an option for treating relapsed multiple myeloma in people who have had 1 previous treatment.  It is recommended only if the conditions in the managed access agreement for daratumumab plus bortezomib plus dexamethasone are followed.

This recommendation is not intended to affect treatment with daratumumab plus bortezomib plus dexamethasone that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

More evidence on daratumumab, with bortezomib and dexamethasone, is being collected until January 2021. After this, NICE will decide whether or not to recommend it for use on the NHS and update the guidance.

NICE’s guidance is informed by an evidence review group report prepared by SHTAC, which critically appraised the drug company’s submission to NICE’s Single Technology Appraisal process.

For more information about SHTAC’s previous research into cancer please visit our Research page.

 

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×